Silo Pharma, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC on November 13, 2026, disclosing consolidated balance sheet data and financial results for the three and nine months ended September 30, 2026.

Key Highlights

  • Cash position: Cash and cash equivalents stood at $6,088,184 as of September 30, 2026, up from $4,748,700 at December 31, 2025.
  • Total assets: Total assets were $8,796,265 as of September 30, 2026, compared with $7,605,100 at December 31, 2025.
  • Short-term investments: Short-term investments at fair value were $1,962,811 as of September 30, 2026, down from $2,110,065 at December 31, 2025.
  • Crypto assets: Crypto assets at fair value were $307,338 as of September 30, 2026, compared with $221,817 at December 31, 2025.
  • Current liabilities: Total current liabilities decreased to $351,453 as of September 30, 2026, from $650,183 at December 31, 2025.
  • Shares outstanding: Common shares outstanding as of November 13, 2026 were 2,156,292, with 37,273 shares held in treasury.

Silo Pharma's September 30, 2026 Financial Position

According to the filing, Silo Pharma, Inc. (NASDAQ:SILO) reported total current assets of $8,587,703 as of September 30, 2026, compared with $7,387,725 at December 31, 2025. The increase was driven primarily by growth in cash and cash equivalents, which rose by approximately $1.34 million over the nine-month period. Short-term investments at fair value declined modestly from $2,110,065 to $1,962,811 over the same period.

The company disclosed that crypto assets at fair value increased to $307,338 at September 30, 2026, from $221,817 at December 31, 2025. The filing also notes that crypto assets previously carried at cost of $98,584 at December 31, 2025 had a zero balance at September 30, 2026. Intangible assets, net, were reported at $208,562 as of September 30, 2026, down from $217,375 at year-end 2025, bringing total long-term assets to $208,562.

On the liabilities side, the filing reported that accounts payable and accrued expenses fell to $351,453 from $578,081, and deferred revenue carried a current portion of $72,102 at December 31, 2025 that was reduced to zero by September 30, 2026. The company is classified as a non-accelerated filer and a smaller reporting company. The filing notes that forward-looking statements contained in the report are subject to risks and uncertainties described in the company's cautionary language.

What Was Disclosed

Silo Pharma filed its quarterly report covering the period ended September 30, 2026, disclosing consolidated balance sheet figures showing higher cash and total assets versus year-end 2025, along with reduced current liabilities and 2,156,292 common shares outstanding as of November 13, 2026.